logo-loader

BioSig Technologies to begin first-in-human studies of its PURE EP System at the Mayo Clinic

Published: 12:18 10 Dec 2018 EST

BioSig Technologies Inc (NASDAQ:BSGM) CEO Kenneth Londoner said the medical device company will begin its first-in-human studies at the Mayo Clinic using its PURE EP System at its Jacksonville, Florida hospital.

PURE EP was developed by the Los Angeles based company to improve catheter ablation treatments for heart arrhythmias.

Londoner says the company will approach the commercial market next year.

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

21 minutes ago